National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”) on behalf of investors who purchased MoonLake shares during the period ofMarch 10, 2024 through September 29, 2025 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline: Investors who purchased MoonLakesecurities during the Class Period may, no later than December 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland.
According to the lawsuit,MoonLake and certain executives made false and misleading statements regarding the Company's only drug candidate,sonelokimab (SLK), in testing as a treatment for certain skin conditions. The complaint alleges that the Company repeatedly promoted SLK's Nanobody structure as providing superior clinical advantages over traditional monoclonal antibodies, such as FDA-approved BIMZELX.
OnSeptember 28, 2025, the Company announcedPhase 3 clinical trial results for SLK, which, according to the lawsuit, showedthat SLK failed to achieve efficacy comparable to BIMZELX. Analysts reportedly described the data as a “disastrous result,” andMoonLake's stock declined nearly 90%, or $55.75 per share, in a single trading session.
If you are a MoonLake investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigationsince its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:Andrew AbramowitzSenior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniDirector of Portfolio & Institutional Client Monitoring ServicesBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC00353&sd=2025-10-16
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-moonlake-immunotherapeutics-nasdaq-mltx-investors-after-class-action-filing-302586844.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC00353&Transmission_Id=202510161736PR_NEWS_USPR_____DC00353&DateId=20251016